NCT06089044View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Prosthesis-related Infections
Interventions
DRUG

Dalbavancin Injection

Dalbavancin as long-term suppressive therapy.

Trial Locations (1)

Unknown

CH Tourcoing, Tourcoing

All Listed Sponsors
lead

Tourcoing Hospital

OTHER

NCT06089044 - Evaluation of the Efficacy and Safety of Suppressive Therapy With DALBAVANCINE in Device Infections | Biotech Hunter | Biotech Hunter